Chemed (CHE) Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemed in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CHE shares.
View CHE analyst ratings or view top-rated stocks.

1 equities research analysts have issued twelve-month price objectives for Chemed's stock. Their CHE share price forecasts range from $576.00 to $610.00. On average, they expect the company's stock price to reach $593.00 in the next twelve months. This suggests a possible upside of 15.6% from the stock's current price.
View analysts price targets for CHE or view top-rated stocks among Wall Street analysts.

Chemed's stock was trading at $510.43 at the start of the year. Since then, CHE stock has increased by 0.5% and is now trading at $512.82.
View the best growth stocks for 2023 here.

Chemed saw a drop in short interest during the month of September. As of September 15th, there was short interest totaling 443,600 shares, a drop of 13.3% from the August 31st total of 511,700 shares. Based on an average trading volume of 71,500 shares, the days-to-cover ratio is presently 6.2 days. Approximately 3.0% of the shares of the company are short sold.
View Chemed's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, October 30th 2023.
View our CHE earnings forecast.

Chemed Co. (NYSE:CHE) issued its quarterly earnings data on Wednesday, July, 26th. The company reported $4.71 EPS for the quarter, missing analysts' consensus estimates of $5.09 by $0.38. The business earned $553.80 million during the quarter, compared to analysts' expectations of $562.54 million. Chemed had a trailing twelve-month return on equity of 34.65% and a net margin of 10.36%. The firm's revenue was up 4.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $4.84 EPS.

Chemed announced a quarterly dividend on Friday, August 4th. Shareholders of record on Monday, August 14th will be given a dividend of $0.40 per share on Tuesday, September 5th. This represents a $1.60 annualized dividend and a yield of 0.31%. The ex-dividend date of this dividend is Friday, August 11th. This is a boost from the stock's previous quarterly dividend of $0.38.
Read our dividend analysis for CHE.

ETFs with the largest weight of Chemed (NYSE:CHE) stock in their portfolio include VictoryShares THB Mid Cap ESG ETF (MDCP), Formidable Fortress ETF (KONG), First Trust Dorsey Wright Momentum & Low Volatility ETF (DVOL), Opus Small Cap Value Plus ETF (OSCV), Inspire Faithward Mid Cap Momentum ETF (GLRY), Natixis Vaughan Nelson Select ETF (VNSE), FIS Biblically Responsible Risk Managed ETF (PRAY) and Dividend Performers ETF (IPDP).

Chemed (NYSE:CHE) pays an annual dividend of $1.60 per share and currently has a dividend yield of 0.31%. The company has been increasing its dividend for 15 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 10.67%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CHE will have a dividend payout ratio of 7.17% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for CHE.

Chemed issued an update on its FY 2023 earnings guidance on Wednesday, July, 26th. The company provided EPS guidance of $19.90-$20.10 for the period, compared to the consensus earnings per share estimate of $20.92. The company issued revenue guidance of -.

1 employees have rated Chemed Chief Executive Officer Kevin J. McNamara on Glassdoor.com. Kevin J. McNamara has an approval rating of 100% among the company's employees. This puts Kevin J. McNamara in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemed investors own include AT&T (T), Home Depot (HD), Johnson & Johnson (JNJ), AbbVie (ABBV), Abbott Laboratories (ABT), CVS Health (CVS), Boeing (BA), UnitedHealth Group (UNH), Verizon Communications (VZ) and Chevron (CVX).

Chemed trades on the New York Stock Exchange (NYSE) under the ticker symbol "CHE."

Chemed's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.39%), William Blair Investment Management LLC (3.72%), Kayne Anderson Rudnick Investment Management LLC (3.43%), Durable Capital Partners LP (3.03%), State Street Corp (2.94%) and Impax Asset Management Group plc (1.98%). Insiders that own company stock include David Patrick Williams, Donald E Saunders, Kevin J Mcnamara, Michael D Witzeman, Nicholas Michael Westfall, Patrick P Grace, Spencer S Lee and Thomas P Rice.
View institutional ownership trends.

Shares of CHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CHE stock can currently be purchased for approximately $512.82.

Chemed (NYSE:CHE) has a market capitalization of $7.73 billion and generates $2.13 billion in revenue each year. The company earns $249.62 million in net income (profit) each year or $15.00 on an earnings per share basis.

The company employs 14,167 workers across the globe.

Chemed's mailing address is 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202. The official website for the company is www.chemed.com. The company can be reached via phone at (513) 762-6690 or via fax at 513-762-6590.